Cypher $470 Mil. Q4 Domestic Sales Double Size Of Cordis Unit
This article was originally published in The Gray Sheet
Executive Summary
Cypher drug-eluting stent U.S. sales propelled a 99% Cordis revenue jump in the fourth quarter to $896 mil
You may also be interested in...
Taxus Clears Legal Hurdle As Judge Denies J&J/Cordis Injunction Request
The arguments made by Boston Scientific and Johnson & Johnson/Cordis in the ongoing drug-eluting stent patent dispute both have merit, according to Wilmington, Del. federal court Judge Sue Robinson
Guidant To Seek Review Of $425 Mil. Patent Suit Arbitration Award To Cordis
Guidant stent sales will not be affected by a June 5 arbitration panel finding that the firm infringed Johnson &Johnson/Cordis' Palmaz-Schatz patents, Guidant says
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.